Manifold Bio

If you're attending @PEGSboston, don't miss the talk by our Co-founder and CTO, @PierceOgdenJ, on Manifold Bio's approach to one of the hardest problems in drug development: getting the right drug to the right tissue. Pierce will present our platform, which connects AI-driven protein design to functional readouts in living systems. Using massively parallel molecular multiplexing, Manifold can evaluate hundreds of thousands of designs simultaneously in any biological context, including in vivo. Our multiplexed in vivo screening platform allows simultaneous assessment of tissue distribution across hundreds of receptor candidates in a single study. This enables programmable, selective delivery of diverse therapeutics across the body, driving a pipeline of tissue-targeted medicines. Directly after his talk, Pierce will join a panel on de novo biologics design chaired by @SurgeBiswas (@nablabio), alongside Prashanth Vishwanath (@TakedaPharma) and Maria Wendt (@sanofi). 📅 Friday May 15, 2026 | 10:55 am ET 📍 PEGS Boston - pegsummit.com

Heading to #TIDESUSA? Don't miss the talk by our Co-Founder and CTO, @PierceOgdenJ. Current oligonucleotide delivery technologies are not optimized for diverse tissues and therapeutic product profiles. Pierce will present data from @ManifoldBio's multiplexed in vivo screening platform, which we used to test thousands of AI-designed protein shuttle candidates against hundreds of novel receptors directly in living systems, revealing diverse biodistribution profiles across brain and peripheral tissues and identifying new conjugate partners for improved oligonucleotide delivery. 📅 Wednesday May 13, 2026 | 2:30pm ET 📍 TIDES - informaconnect.com/tides

If you're attending the NOVA Conference hosted by @aginginit, don't miss the talk by our CSO, Kimberly Scearce-Levie. Previously, Kimberly led translational science at Denali Therapeutics, including the biomarker strategy for Hunter syndrome program that recently became the first FDA-approved biologic engineered to cross the blood-brain barrier. At NOVA, she'll share data on @ManifoldBio’s novel shuttles that deliver therapeutics into the brain with greater uptake and improved tolerability over first-generation shuttles. Powering this is Manifold's ability to test hundreds of thousands of designs simultaneously, in vivo. The same engine is delivering tissue-targeted medicines beyond the brain, into adipose, muscle, and other tissues. Delighted to share the stage with @JimGormanMDPhD (@wyssinstitute), Brandi Simpson (Switch Therapeutics), and Kirk Brown (@Alnylam). 🗓 Saturday April 25, 2026 | 2:30–3:30pm ET | Boston, MA 📍NOVA - novaneuro.org

🔗 More about mBER: manifold.bio/news/introduci…

Great to see Manifold’s #mBER AI protein design model in action! As part of the Amazon Bio Discovery launch this week, @AmazonScience performed agent-guided de novo design using three independent methods including @ManifoldBio 's #mBER to design nanobody binders against a novel cancer target, identifying several sub-nanomolar hits. mBER is now available via Amazon Bio Discovery.

🔗 amazon.science/publications/a…

Achievement unlocked: @ManifoldBio highlighted at the @NYSE for being named to @FastCompany 's Most Innovative Companies of 2026. Manifold Bio is building organism-scale AI to transform drug discovery Recent highlights: - Million-scale AI protein design collaboration with #NVIDIA. - $2B collaboration with Roche We’re just getting started.

Read more here: fastcompany.com/91497087/biote…

AI is catalyzing the greatest acceleration of engineering capability in human history. Drug discovery, still serial by nature, hasn't kept pace. One molecule, one experiment at a time, starved of data at the right scale and physiological relevance to fuel AI-guided design. @ManifoldBio is making biology massively parallel, testing hundreds of thousands of drug designs simultaneously in a single experiment, including in living systems. We use this data to build organism-scale models of biology, which, combined with our AI-guided molecular design, power a fundamentally new approach to drug development. We're honored to be named one of @FastCompany 's Most Innovative Companies of 2026. This recognition reflects what's been an extraordinary year for the team: - Broke the 100,000-plex barrier for massively parallel in vivo studies - Released mBER, a state-of-the-art de novo antibody design model - Secured a $2B ($55M upfront) partnership with Roche, the biggest AI x Bio deal of the past 4 years - Ran a world-first with @NVIDIAHealth : 1 million AI-designed binders. 127 targets. 100M+ protein-protein interactions. One experiment. We're bringing biology into the digital realm. This is just the beginning.

@adpdnet 🗓 Saturday March 21, 2026 | 11:55–12:10 CET 📍Copenhagen, Denmark

@adpdnet Underlying this work, and central to Manifold's pipeline of tissue-targeted medicines, is our multiplexed in vivo screening platform that allows simultaneous assessment of tissue distribution across hundreds of receptor candidates in a single study.

If you're at #ADPD2026, don't miss Naveen Mehta’s talk on @ManifoldBio’s approach to one of the core challenges in treating neurodegenerative diseases: getting drugs across the blood-brain barrier.

The study between @ManifoldBio and @NvidiaHealth generated thousands of new annotated structures for future model training. and sets a new benchmark for matching the throughput of generative AI models with experimental validation at equivalent scale. 👉 research.nvidia.com/labs/genair/pr…

This method was first demonstrated by @ManifoldBio last October. We tested 1.1M VHH antibody designs against 145 targets, measuring 100M+ protein-protein interactions to validate #mBER, the company’s AI library for designing epitope-specific antibodies. 👉 manifold.bio/news/introduci…

@ManifoldBio and @NVIDIAHealth announce a joint study validating Proteina-Complexa, NVIDIA's latest BioNeMo model for protein binder design.